CD274 and neoplasm: We observed that nintedanib alone or when combined with PD-L1 antibody did not show any benefit when used to treat advanced metastatic disease in the EMT-6/CDDP cell line (Fig. 5), despite the antitumor effect induced by this combination in the primary tumor setting (Fig. 4b).